Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (AU:ATH) ) just unveiled an update.
Alterity Therapeutics announced the filing of its Annual Report on Form 20-F with the SEC, including audited financial statements for the year ending June 30, 2025. This filing, along with the XBRL interactive data, is available on their website, reflecting the company’s commitment to transparency and regulatory compliance, which could bolster stakeholder confidence and enhance its industry positioning.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company has demonstrated efficacy in its lead asset, ATH434, through clinical trials for Multiple System Atrophy (MSA), and it operates from Melbourne, Australia, and San Francisco, USA.
YTD Price Performance: 40.0%
Average Trading Volume: 13,444,263
Technical Sentiment Signal: Sell
Current Market Cap: A$128.9M
See more insights into ATH stock on TipRanks’ Stock Analysis page.